| pubmed-article:16643206 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16643206 | lifeskim:mentions | umls-concept:C0220847 | lld:lifeskim |
| pubmed-article:16643206 | lifeskim:mentions | umls-concept:C0019682 | lld:lifeskim |
| pubmed-article:16643206 | lifeskim:mentions | umls-concept:C0019699 | lld:lifeskim |
| pubmed-article:16643206 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16643206 | lifeskim:mentions | umls-concept:C0019069 | lld:lifeskim |
| pubmed-article:16643206 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:16643206 | lifeskim:mentions | umls-concept:C0005779 | lld:lifeskim |
| pubmed-article:16643206 | lifeskim:mentions | umls-concept:C0235378 | lld:lifeskim |
| pubmed-article:16643206 | lifeskim:mentions | umls-concept:C1744681 | lld:lifeskim |
| pubmed-article:16643206 | lifeskim:mentions | umls-concept:C0439148 | lld:lifeskim |
| pubmed-article:16643206 | lifeskim:mentions | umls-concept:C1719822 | lld:lifeskim |
| pubmed-article:16643206 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:16643206 | pubmed:dateCreated | 2006-4-28 | lld:pubmed |
| pubmed-article:16643206 | pubmed:abstractText | The aim of the study was to assess the incidence and the cumulative probability of cytolytic and cholestatic hepatotoxicity during antiretroviral treatment in a group of HIV HCV haemophiliacs. We evaluated 47 patients that received 246 courses of antiretroviral treatment [98 courses of pre-highly active antiretroviral therapy (pre-HAART) and 148 HAART treatments]. Liver function tests were assessed at baseline of each treatment, after 1 month and at least every 4 months thereafter. Cytolytic and cholestatic hepatotoxicity was recorded. Of the 246 treatments, 28 (12.45%) were followed by cytolytic hepatotoxicity and 32 (13%) by cholestatic hepatotoxicity. Cytolytic hepatotoxicity was similar in HAART (16/148; 10.8%) and in pre-HAART treatment (12/98; 12.2%) and cholestatic hepatotoxicity was more frequent in HAART (29/148; 19.6%) than in pre-HAART treatment (3/98; 3.1%) (P < 0.001). The actuarial probability of developing cytolytic and cholestatic hepatotoxicity at 10 years of onset of antiretroviral treatments was 39% and 56%, respectively. Most enzyme elevations were asymptomatic, but in eight cases therapy was discontinued or changed and in one case a cirrhotic patient died of progressive liver failure. In HIV HCV haemophiliacs, the cumulative probability of developing hepatotoxicity during follow-up is high and although in the most cases the toxicity is mild, fatal cases can occur. | lld:pubmed |
| pubmed-article:16643206 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16643206 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16643206 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16643206 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16643206 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16643206 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16643206 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16643206 | pubmed:month | May | lld:pubmed |
| pubmed-article:16643206 | pubmed:issn | 1351-8216 | lld:pubmed |
| pubmed-article:16643206 | pubmed:author | pubmed-author:GuardiaJJ | lld:pubmed |
| pubmed-article:16643206 | pubmed:author | pubmed-author:EstebanRR | lld:pubmed |
| pubmed-article:16643206 | pubmed:author | pubmed-author:VargasVV | lld:pubmed |
| pubmed-article:16643206 | pubmed:author | pubmed-author:MartorellMM | lld:pubmed |
| pubmed-article:16643206 | pubmed:author | pubmed-author:RuizII | lld:pubmed |
| pubmed-article:16643206 | pubmed:author | pubmed-author:TuranAA | lld:pubmed |
| pubmed-article:16643206 | pubmed:author | pubmed-author:PuigLL | lld:pubmed |
| pubmed-article:16643206 | pubmed:author | pubmed-author:EstebanJ IJI | lld:pubmed |
| pubmed-article:16643206 | pubmed:author | pubmed-author:SauledaSS | lld:pubmed |
| pubmed-article:16643206 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16643206 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:16643206 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16643206 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16643206 | pubmed:pagination | 228-36 | lld:pubmed |
| pubmed-article:16643206 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:meshHeading | pubmed-meshheading:16643206... | lld:pubmed |
| pubmed-article:16643206 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16643206 | pubmed:articleTitle | Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade. | lld:pubmed |
| pubmed-article:16643206 | pubmed:affiliation | Blood Bank (CTBT), Hospital Vall d'Hebron, Spain. | lld:pubmed |
| pubmed-article:16643206 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16643206 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16643206 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16643206 | lld:pubmed |
